Investments
138Portfolio Exits
32Funds
5Service Providers
1About Longitude Capital
Longitude Capital specializes in making venture growth investments in biotechnology and medical technology companies that seek to improve clinical outcomes, enhance quality of life and/or reduce system costs. The Firm's growth strategy is rooted in building a balanced portfolio of clinical-stage and commercial-stage companies with clinically de-risked assets, favorable valuations relative to risk profile and attractive expected returns within three to five years from initial investment. Additionally, Longitude Capital utilizes a variety of investment structures, including traditional venture capital, asset spin-outs, recapitalizations, PIPEs, open market purchases, royalties and other equity and equity-linked instruments.
Want to inform investors similar to Longitude Capital about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Expert Collections containing Longitude Capital
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find Longitude Capital in 1 Expert Collection, including Conference Exhibitors.
Conference Exhibitors
5,302 items
Latest Longitude Capital News
Aug 3, 2023
Current investors Acorn Bioventures, Decheng Capital, Ally Bridge Group, Malin Corporation, RA Capital Management and Longitude Capital also took part in the round. CG Oncology plans to use the oversubscribed financing to progress clinical programmes in bladder cancer and obtain approval from the US Food and Drug Administration (FDA). The programmes include the single-arm, Phase III BOND-003 monotherapy clinical trial of cretostimogene grenadenorepvec. This could potentially treat patients with high-risk non-muscle invasive bladder cancer (NMIBC) not responsive to bacillus Calmette-Guerin (BCG). Cretostimogene grenadenorepvec is an oncolytic immunotherapy agent administered intravesically. It is being evaluated in a Phase II trial along with Keytruda (pembrolizumab) for the same indication. The agent is also being analysed along with Opdivo (nivolumab) for the treatment of other bladder cancer types. CG Oncology CEO Arthur Kuan stated: “We are excited to welcome leading life science investors who share our vision of developing cutting-edge therapeutics addressing unmet medical needs in bladder cancer. “Our lead asset, cretostimogene grenadenorepvec, continues to make significant clinical progress in bladder cancer in both monotherapy and combination studies. We are encouraged to see our treatments get closer to being available to bladder cancer patients worldwide.” Share this article
Longitude Capital Investments
138 Investments
Longitude Capital has made 138 investments. Their latest investment was in CG Oncology as part of their Series F on August 8, 2023.
Longitude Capital Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
8/2/2023 | Series F | CG Oncology | $105M | No | 4 | |
5/24/2023 | Seed VC | WKCGRG Holdings | $0.83M | Yes | 1 | |
4/17/2023 | Series D | Cortica | $75M | No | 4 | |
2/20/2023 | Series B | |||||
2/17/2023 | Series D |
Date | 8/2/2023 | 5/24/2023 | 4/17/2023 | 2/20/2023 | 2/17/2023 |
|---|---|---|---|---|---|
Round | Series F | Seed VC | Series D | Series B | Series D |
Company | CG Oncology | WKCGRG Holdings | Cortica | ||
Amount | $105M | $0.83M | $75M | ||
New? | No | Yes | No | ||
Co-Investors | |||||
Sources | 4 | 1 | 4 |
Longitude Capital Portfolio Exits
32 Portfolio Exits
Longitude Capital has 32 portfolio exits. Their latest portfolio exit was AEON Biopharma on December 22, 2022.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
12/22/2022 | Reverse Merger | 3 | |||
12/21/2021 | Acquired | 10 | |||
10/7/2021 | IPO | Public | 11 | ||
Date | 12/22/2022 | 12/21/2021 | 10/7/2021 | ||
|---|---|---|---|---|---|
Exit | Reverse Merger | Acquired | IPO | ||
Companies | |||||
Valuation | |||||
Acquirer | Public | ||||
Sources | 3 | 10 | 11 |
Longitude Capital Acquisitions
2 Acquisitions
Longitude Capital acquired 2 companies. Their latest acquisition was Ajax Vascular on November 26, 2014.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
|---|---|---|---|---|---|---|
11/26/2014 | Series A | $1.5M | Asset Sale | |||
8/20/2014 | Debt |
Date | 11/26/2014 | 8/20/2014 |
|---|---|---|
Investment Stage | Series A | Debt |
Companies | ||
Valuation | ||
Total Funding | $1.5M | |
Note | Asset Sale | |
Sources |
Longitude Capital Fund History
5 Fund Histories
Longitude Capital has 5 funds, including Longitude Capital Prime Fund I.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
|---|---|---|---|---|---|
7/20/2021 | Longitude Capital Prime Fund I | $135M | 1 | ||
9/23/2020 | Longitude Venture Partners IV | ||||
6/7/2016 | Longitude Venture Partners III | ||||
10/22/2012 | Longitude Venture Partners II | ||||
6/16/2008 | Longitude Venture Partners |
Closing Date | 7/20/2021 | 9/23/2020 | 6/7/2016 | 10/22/2012 | 6/16/2008 |
|---|---|---|---|---|---|
Fund | Longitude Capital Prime Fund I | Longitude Venture Partners IV | Longitude Venture Partners III | Longitude Venture Partners II | Longitude Venture Partners |
Fund Type | |||||
Status | |||||
Amount | $135M | ||||
Sources | 1 |
Longitude Capital Service Providers
1 Service Provider
Longitude Capital has 1 service provider relationship
Service Provider | Associated Rounds | Provider Type | Service Type |
|---|---|---|---|
Counsel |
Service Provider | |
|---|---|
Associated Rounds | |
Provider Type | Counsel |
Service Type |
Partnership data by VentureSource
Longitude Capital Team
13 Team Members
Longitude Capital has 13 team members, including current Founder, Managing Director, Juliet Tammenoms Bakker.
Name | Work History | Title | Status |
|---|---|---|---|
Juliet Tammenoms Bakker | Pequot Capital Mangement | Founder, Managing Director | Current |
Name | Juliet Tammenoms Bakker | ||||
|---|---|---|---|---|---|
Work History | Pequot Capital Mangement | ||||
Title | Founder, Managing Director | ||||
Status | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
